We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPIC
626
DELISTED
TPI Composites
TPIC
| $739K | 0.01% |
+31,631
| New | +$594K |
|
627
Ingersoll Rand
IR
$33.9B
| $733K | 0.01% |
+26,057
| New | +$736K |
|
628
Arch Capital
ACGL
$37.2B
| $731K | 0.01% |
25,509
-8,464
| -25% | -$234K |
|
|
HDS
629
DELISTED
HD Supply Holdings, Inc.
HDS
| $731K | 0.01% |
21,089
-7,210
| -25% | -$224K |
|
630
Cincinnati Financial
CINF
$28B
| $730K | 0.01% |
11,407
-3,843
| -25% | -$254K |
|
631
Markel Group
MKL
$25.5B
| $723K | 0.01% |
783
-462
| -37% | -$420K |
|
632
Assurant
AIZ
$14B
| $720K | 0.01% |
6,966
-902
| -11% | -$93.4K |
|
633
HubSpot
HUBS
$12.2B
| $718K | 0.01% |
3,200
+1,920
| +150% | +$345K |
|
634
MGM Resorts International
MGM
$11.8B
| $704K | 0.01% |
41,917
-215,682
| -84% | -$3.48M |
|
635
Lumen
LUMN
$6.38B
| $701K | 0.01% |
69,841
-45,480
| -39% | -$455K |
|
636
MongoDB
MDB
$25B
| $699K | 0.01% |
+3,086
| New | +$572K |
|
637
Equity Lifestyle Properties
ELS
$12.8B
| $698K | 0.01% |
11,175
-2,825
| -20% | -$173K |
|
|
BMY.RT
638
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $697K | 0.01% |
194,693
-49,925
| -20% | -$180K |
|
|
AVDL
639
DELISTED
Avadel Pharmaceuticals
AVDL
| $687K | 0.01% |
+85,000
| New | +$749K |
|
640
Franco-Nevada
FNV
$40.6B
| $685K | 0.01% |
4,917
-1,106
| -18% | -$147K |
|
|
CTLT
641
DELISTED
CATALENT, INC.
CTLT
| $685K | 0.01% |
+9,344
| New | +$634K |
|
|
SIVB
642
DELISTED
SVB Financial Group
SIVB
| $684K | 0.01% |
3,173
-2,093
| -40% | -$403K |
|
643
EMQQ The Emerging Markets Internet & Ecommerce ETF
EMQQ
$268M
| $683K | 0.01% |
14,620
+6,660
| +84% | +$258K |
|
644
Tilly's
TLYS
$118M
| $680K | 0.01% |
+120,000
| New | +$618K |
|
645
Diamondback Energy
FANG
$53.5B
| $677K | 0.01% |
16,191
-26,405
| -62% | -$1.08M |
|
646
Steel Dynamics
STLD
$37.5B
| $677K | 0.01% |
25,958
+1,259
| +5% | +$31.5K |
|
647
Sun Communities
SUI
$15.3B
| $673K | 0.01% |
4,963
-2,362
| -32% | -$314K |
|
|
VER
648
DELISTED
VEREIT, Inc.
VER
| $673K | 0.01% |
20,938
-4,501
| -18% | -$125K |
|
649
LKQ Corp
LKQ
$6.77B
| $672K | 0.01% |
+25,665
| New | +$632K |
|
650
Jack Henry & Associates
JKHY
$11.2B
| $660K | 0.01% |
+3,587
| New | +$625K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.